Business
Admission To Trading For Placing Shares
Admission To Trading For Placing Shares.

About this update from Capai Plc
[{"type":"text","content":"\n \n \n RNS Number : 9993L\n Dukemount Capital PLC\n 05 May 2020\n \n \n \n \n Dukemount Capital PLC\n \n \n 05 May 2020 \n \n \n \n \n \n \n \n \n \n \n \n 05 May 2020\n \n \n \n \n \n Dukemount Capital Plc\n \n \n (\"Dukemount\" or \"the Company\")\n \n \n \n \n \n Admission To Trading For Placing Shares\n \n \n \n \n \n \n \n \n It was previously announced on 22 April 2020 that the Company had raised, in aggregate, £255,034.50 before expenses, by way of a placing of 72,867,000 new ordinary shares (the \"Placing Shares\") at a price of 0.35 pence per share. \n \n \n Admission to trading for these Placing shares is now expected to be on 6 May 2020.\n \n \n Following Admission, the Company will have 439,033,666 ordinary shares in issue, none of which will be held in treasury. Accordingly, the total number of voting rights in the Company will be 439,033,666 and shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.\n \n \n \n For further information, please visit www.dukemountcapitalplc.com or contact:\n \n \n \n \n \n \n Dukemount Capital Plc\n \n \n Via St Swithins PR\n \n \n \n \n Geoffrey Dart\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n St Swithins PR (Media and Investor Enquiries)\n \n \n Tel: +44 (0) 1732 521132\n \n \n \n \n Gary Middleton\n \n \n \n \n [email protected]\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Peterhouse Capital Limited\n \n \n Tel: +44 (0) 207 469 0930\n \n \n \n \n Lucy Williams/Duncan Vasey\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.\n END\n \n IOEBDGDUGDGDGGU\n ","length":5862,"tagName":"div"}]